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ABSTRACT A glycoprotein binding complement component
C3d was isolated from media used for culture of Raji human lym-
phoblastoid cells. Analysis by sodium dodecyl sulfate/polyacryl-
amide gel electrophoresis. and gas/liquid chromatography indi-
cated that the C3d-binding glycoprotein consisted of a single
polypeptide chain with extensive intrachain. disulfide bonds, a
molecular weight of 72,000, and several different bound carbo-
hydrates. Several, lines of evidence-indicated that this medium-
derived C3d-binding protein originated from membrane comple-
ment receptor type two (CR2, the C3d receptor), presumably shed
during membrane turnover. The C3d-binding protein bound to
sheep erythrocytes coated with C3d (EC3d) but not to sheep eryth-
rocytes coated with C3b (EC3b). Antisera, prepared by immuni-
zation with the purified C3d-binding glycoprotein, inhibited lym-
phocyte rosette formation with EC3d but not with ECAb. Analysis
by sodium dodecyl sulfate gel electrophoresis of the radiolabeled
and. solubilized lymphocyte antigens reactive with the anti-C3d-
binding protein sera revealed a single-chain cell-surface protein
of molecular weight 72,000 that was apparently identical to the
isolated C3d-binding protein. Parallel assay of lymphocytes for
CR2 by direct immunofluorescence withlF(ab')2 anti-C3d-binding
protein (anti-CR2) and rosette formation with EC3d indicated that
both assays had the same specificity and nearly the same sensi-
tivity. With both systems CR2 expression was limited to B cells,
and was undetectable on T cells, monocytes, or neutrophils.
Bone marrow-derived (B) lymphocytes express two distinct
types of membrane receptors for the third component of com-
plement (C3) (1), a receptor for f1lH globulin (2) and' surface-
bound C5 (3). Complement (C) receptor type one (CR1, the C3b
receptor) has recently been isolated and shown to be a 205,000
Mr glycoprotein (4). Isolated CR1 bound to both C4b, and Cab,
and lymphocytes treated with Fab' anti-CRI did not form ro-
settes with the erythrocyte-complement complexes EC3b or
EAC14b (5). Previous attempts to isolate lymphocyte C rectep-
tor type two (CR2, the C3d receptor) have been unsuccessful
(6). CR2 differs from CRI in that it is expressed exclusively on
lymphocytes, whereas CR1 is also expressed on monocytes,
neutrophils, erythrocytes, and, kidney cells (7). Although the
functions of CR1 and.CR2 are unknown, B colls do respond to
either 81H receptor triggering or the cleavage of surface C5
by releasing endogenous C3b inactivator (C3bINA) (2, *).
In the present study, media from B-type lymphoblastoid cells
were shown to contain a soluble C3d-binding protein. This C3d-
binding protein was purified and found to be a glycoprotein of
72,000 Mr. Antibody prepared by immunization of rabbits with
the C3d-binding protein inhibited lymphocyte rosette forma-
tion with EC3d'but not with EC3b, and reacted with a single
cell-surface protein of 72,000 Mr.
MATERIALS AND METHODS
Lymphoid Cells, Neutrophils, and Spent Culture Media.
Normal human blood mononuclear cells and neutrophils were
isolated on a two-step (1.08 g/ml and 1.105 g/ml) Ficoll/Hy-
paque density gradient (5, 8), whereas tonsil cells were isolated
on 1.08 g/ml Ficoll/Hypaque (9). Monocytes were either re-
moved with Sephadex G-10 (Pharmacia) (10) or labeled with
latex (11). The human B-cell lines Raji, Daudi, and BF, and the
HSB T-cell line, were maintained at 0.8-2.0 X 10' cells per ml
by doubling the culture volume at 2-day intervals with RPMI-
1640 medium containing 10% fetal bovine serum, penicillin,
and streptomycin. Spent culture media was harvested by cen-
trifugation and stored frozen at -850C.
C Components and C-Coated Sheep Erythrocytes (EC and
EAC). C components and nephritic factor (NF) were isolated
and used to prepare CRI-reactive EAC14b and EC3b as de-
scribed (2, 12). EC3b was converted into EC3bi and EC3d with
KSCN-inactivated serum (12) and plasmin (2). Fixation of C3
onto EC3'was monitored with [3H]C3 (2, 13).
C-Receptor and Surface Ig Assays. C receptors and surface
Ig were detected by rosette assay and immunofluorescence,
respectively (2, 12, 14). Fluid-phase C3d-binding protein (CR2)
was detected by two different assays with EC3d containing 1.5
X 103 C3d molecules per EC3d complex. First, serial 25-,ul
dilutions of CR2 sample were tested for inhibition of Raji
cell-EC3d rosette formation by microtiter assay (6). Second,
soluble CR2 was detected by microtiter assay for inhibition of
EC3d agglutination by anti-C3d. Serial 25-,ul dilutions of CR2
sample in a U-bottom plate were mixed with 25 ,ul of EC3d
(1 X 108 per ml) and incubated on a shaker at 37°C for 15 min,
after which time 25 ,ul of a 1:24 dilution of anti-C3d serum
(kindly provided by Brian F. Tack, Harvard Medical School,
Boston) was added to each well. After 15-min shaking at 370C,
the cells were allowed to settle for development of agglutination
patterns.
Binding of 3H-Labeled Lymphoid Components to EC3 and
EAC14b. One-hundred microliters of 3H-labeled Raji culture
media (2) was mixed with 100 ,.lof E, EAC14b, EC3b, or EC3d
(2 x 108 per ml) in Veronal-buffered (3.5 mM, pH 7.2) 1% bo-
vine serum albumin/3.2% dextrose/0.2% NaNJ30 mM NaCl,
Abbreviations: B lymphocytes or B cells, bone marrow-derived lym-
phocytes; C, complement; CR1, complement receptor type one
(C3b-C4b receptor); CR2. complement receptor type two (C3bi-C3d
receptor); CR3, complement receptor type three (C3bi receptor);
C3bINA, C3b-inactivator; E, erythrocyte; EAC, erythrocyte-
antibody-complement complex; EC, erythrocyte-complement com-
plex, NF, nephritic factorNP-40, Nonidet P40; T lymphocytes or T
cells, thymus-derived lymphocytes.
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and incubated on a rotator for 15 min at 37°C. After three washes
with 1% bovine serum albumin in phosphate-buffered saline,
each cell type was solubilized with 1 ml of NCS solution
(Amersham) and radioactivity was measured in 10 ml of OCS
scintillation fluid (Amersham).
Molecular Weight and Carbohydrate Analysis. Proteins
were treated with 2% NaDodSO4, either with or without 0.1
M dithiothreitol, at 100°C for 5 min and then electrophoresed
in 7% polyacrylamide gels (15). Molecular weight was deter-
mined from mobility by comparison to known markers. Coom-
assie blue-stained bands were cut out of the gel slab and ana-
lyzed for carbohydrates by gas/liquid chromatography after
protein elution with NaDodSO4 and precipitation with trichlo-
roacetic acid (16).
Evaluation of Antibody Specificity for Lymphoid Cell Com-
ponents. Lymphoid cells were either labeled with "2I and lac-
toperoxidase (17) or labeled endogenously by culture in
[3H]leucine (2). F(ab')2 antibodies, prepared with pepsin and
Sephadex G-150 (Pharmacia) (11), were conjugated to Sepha-
rose CL4B (Pharmacia) with cyanogen bromide (18) at a ratio
of 10 mg of protein per ml of gel. Radiolabeled cells (1 X 108)
were solubilized with 1% Nonident P40 (NP40; Particle Data
Laboratories, Elmhurst, IL) in 50 mM Tris1HCl, pH 7.5, con-
taining 2 mM phenylmethylsulfonyl fluoride, soybean trypsin
inhibitor, at 50 gg/ml, 25.mM benzamidine, 10 mM EDTA,
50 mM e-aminocaproic acid, and 10 mM KCI, and then insol-
uble debris was removed by centrifugation at 40,000 X g for
16.hr. The solubilized cells were cycled two times through a
column containing 2 ml of F(ab')2 antibody-Sepharose CL4B
in phosphate-buffered saline and then, after a wash with phos-
phate-buffered 0.3 M NaCV1% Triton X-100 (Sigma)/0.5%
deoxycholate, the bound antigens were eluted with 4 M guani-
dine. The eluate was dialyzed versus 62.5 mM Tris HCl, pH
6.8, concentrated to 1 ml with polyethylene glycol powder,
treated with 2% NaDodSO4 either with or without 0.1 M di-
thiothreitol for 5 min at 100°C, and electrophoresed in 7% poly-
acrylamide gels (15). After electrophoresis, the gel tracks were
sliced into 2-mm segments whose radioactivities were measured
either directly ("~I) or in-OCS after solubilization overnight in
30% (wt/wt) H202 at 56°C (3H).
Preparation of C3d-Sepharose for Affinity Chromatogra-
phy. Five milliliters of.trypsin-Sepharose, prepared with 3 mg
of trypsin per ml of gel (18), was mixed with 20 mg of C3 for
2 min at 37°C and then washed three times by centrifugation.
A NF-stabilized C3-convertase was then assembled on the tryp-
sin-generated Sepharose-bound C3b by addition of 16 mg of
factor B, 16 -;Lg of factor D, and 11.5 mg of NF. After 10 min
at 37C, 100 mg of C3 was added and incubation was continued
for 60 min at 37C. The gel was washed two times, resuspended
in 35 ml of fresh serum, and incubated 60 min at 37°C. C3b
fixation, monitored with 3H-labeled C3, was 2.8 mg per ml of
gel, of which most was presumably converted to C3bi by the
serum C3bINA. Bound C3bi was then degraded to C3d with
plasmin (2) at 60 jig/ml for 30 min at 37°C.
RESULTS
Evidence for a Lymphocyte-Derived C3d-Binding Protein
in Culture Media from B-Type Lymphoblastoid Cell Lines.
Three findings indicated that B-type lymphoblastoid cells syn-
thesized and released a C3d-binding protein resembling CR2.
First, 40-fold concentrated (PM-10 membrane, Amicon, Lex-
ington, MA) spent culture media from both Raji and Daudi cells
inhibited lymphocyte-EC3bi and -EC3d rosette formation to
a titer of 32-64, but did not inhibit formation of EC3b or
EAC14b rosettes. By contrast, media from T-type HSB cells
did not inhibit eitherEC3d or EC3b rosette formation. Second,
media from Raji cells grown in [3H]leucine contained a 3H-la-
beled protein that bound to EC3d but did not bind to E, EC3b,
or EAC14b (Fig. 1). Finally, 40-fold concentrated media from
Raji and Daudi, but not HSB, inhibited the agglutination of
EC3d by anti-C3d to a titer of 1600-3200.
Isolation of the C3d-Binding Protein from Raji Spent Cul-
ture Medium. Most of the C3d-binding activity and 20% of the
protein was precipitated from 15 liters of Raji spent culture
medium by addition of an equal volume of saturated ammonium
sulfate and centrifugation at 15,000 x g for 30 min. After dialysis
against 20 mM sodium phosphate buffer, pH 7.5, the dissolved
precipitate was applied to a 2.6 X 60 cm column of DEAE-Se-
phacel (Pharmacia) equilibrated with the dialysis buffer. Bound
proteins were eluted with a 3-liter linear gradient progressing
to 0.3 M NaCl. Inhibition of anti-C3d agglutination activity was
detected in four distinct eluted peaks (Fig. 2). The fractions
composing each peak were separately pooled, concentrated
(PM-10 membrane) to 15 ml, and chromatographed on a 5 X
90 cm column of Sephadex G-150 in phsphate-buffered saline
(Fig. 3). When assayed by inhibition of anti-C3d agglutination,
activity eluted in three peaks with calculated-molecular weights
of 50,000, 100,000, and >250,000. By contrast, with assays for
inhibition of lymphocyte-EC3d rosettes, activity was restricted
primarily to the excluded volume (>250,000 Mr). Each of the
three Sephadex G-150 pools was dialyzed against pH 7.2 Ve-
ronal-buffered 3.2% dextrose/0.2% NaNJ30 mM NaCl (6.0
mS at 22°C) and applied separately to a-0.5 x 2 cm column of
C3d-Sepharose. After a 200-ml wash with 0.6 M NaCV20% su-
crose in 10 mM phosphate buffer, pH 7.5, the column was
eluted with 0.1% NP-40/0.6 M NaCl in 10 mM phosphate
buffer, pH 7.5. C3d-binding activity was recovered from each
of the activity peaks from DEAE-Sephacel that were chromato-
graphed on both Sephadex G-150 and C3d-Sepharose. The
greatest specific activity and yield was obtained from processing
the fourth peak from DEAE-Sephacel (Fig. 2) and the third
peak from Sephadex G-150 (Fig. 3) through C3d-Sepharose,
resulting in a 2-mg (A2w) yield.
Characteristics of the Isolated C3d-Binding Protein. After
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FIG. 1. Uptake of 3H-labeled protein from Raji cell medium onto
EC3d. Medium from Raji cells cultured in [3H]leucine was added to
EC3d (o), EC3b (e), EAC14b.(o), or E (A) and then, after three washes,
the amount of bound 3H was determined.
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FIG. 2. DEAE-Sephacel column chromatography of the 50% ammonium sulfate precipitate of Raji cell medium.
and Sephadex G-150 had been eluted from C3d-Sepharose,
each was analyzed by NaDodSO4 gel electrophpresis. With
each pool, primarily only one protein was observed of 50,000
Mr without reduction and 72,000 Mr with reduction of disulfide
bonds (Fig. 4). When this single gel protein band was analyzed
for carbohydrates by gas/liquid chromatography, three out of
six sugars present were identified with available standards as
galactose, mannose, and glucosamine.
Preparation and Characteristics of Antibody Specific for
the C3d-Binding Protein. Two rabbits were immunized weekly
with 100 jg of purified C3d-binding protein emulsified in
Freund's complete adjuvant. Immune sera obtained after 6
weeks, but not preimmune sera, inhibited completely EC3d
rosette formation with all lymphocyte types (Table 1). Multiple
absorptions of the two antisera with immobilized human serum
(18) had no effect on the lymphocyte-EC3d rosette inhibition
0.8 IgG BSA OVA
1 JpWI
titer. F(ab')2 antibody at 300 jug/ml inhibited lymphocyte-EC3d
rosette formation completely, whereas at 3.0 mg/ml it did not
inhibit EC3b rosette formation with lymphocytes or neutro-
phils. A range of 0. 3-3.0 mg/ml of this antibody inhibited lym-
phocyte-ECbi rosette formation by only 50-60% but had no
effect on neutrophil-EC3bi rosette formation.
The radiolabeled and solubilized lymphocyte surface and
cytoplasmic components eluted from F(ab')2 anti-C3d binding
protein-Sepharose were analyzed by NaDodSO4 gels. With
either BF cells labeled with "I and lactoperoxidase or Raji cells
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FIG. 3. Sephadex G4150 column chromatography of the last elut-
ing activity peak. obtained from DEAE-Sephacel (see Fig. 2). The mo-
lecular weight of each activity peak was.determined from a previous
calibration run with known markers: human IgG (150,000 Mr), bovine
serum albumin (BSA, 68,000 Mr), and ovalbumin (OVA, 43,000 Mr).
FIG.. 4. AnalysisoftheisolatedC3d-bindingproteinbyNaDodSO4
polyacrylamide gel electrophoresis. The outer tracks contained known
molecular weight markers: myosin (200,000 Mr), -3-galactosidase
(116,500 Mr), phosphorylase b (94,000 Mr), bovine serum albumin
(68,000 Mr), and ovalbumin (43,000 Mr). Tracks a-c contained unre-
duced proteins and d-f, reduced. Two different pools of C3d-binding
activity were electrophoresed unreduced (b, c) and reduced (d, e).
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Table 1. Inhibition of lymphocyte and neutrophil EC3 rosette
formation by F(ab')2 anti-C3d-binding protein
Inhibition of rosette
Antibody-treated formation, %
C-receptor cell EC3b EC3bi EC3d
Blood lymphocytes 0 62 100
Tonsil lymphocytes 0 42 100
Lymphoblastoid cells
Raji (CR(- CR2 ) NT 51 100
Daudi (CR1- CR2 ) NT 52 100
BF (CR1+ CR2 ) 0 64 100
Blood neutrophils 0 0 NT
NT, not tested because the C-receptor cells lacked either CR1 (Raji
and Daudi) or CR2 (neutrophils) and did not form EC3b or EC3d ro-
settes, respectively.
was detected (Fig. 5); it had identical molecular weight char-
acteristics as the isolated C3d-binding protein (Fig. 4).
Immunofluorescence with Anti-C3d-Binding Protein. Im-
munofluorescence assays with F(ab')2 anti-C3d-binding protein
gave results similar to those obtained by parallel EC3d rosette
assays. With normal blood lymphocytes, anti-C3d-binding pro-
tein fluorescence (fluorescein) was observed only on anti-Ig-
rhodamine-positive B cells and not on sheep E-rosette-positive
T cells. Neutrophils and monocytes did not form EC3d rosettes
nor stain with F(ab')2 anti-C3d-binding protein.
DISCUSSION
The possibility of shed C receptors in lymphoblastoid cell cul-
ture media was previously suggested by the finding of EAC
rosette-inhibiting activity in B but not T cell media, and by the
demonstration that C receptors were regenerated rapidly dur-
ing membrane turnover (19). In the present study this rosette-
inhibiting activity was shown to be due to a lymphocyte-derived
1U
glycoprotein that bound to EC3d but not to EC3b or EAC14b,
and resembled monovalent Fab anti-C3d in that it inhibited
bivalent anti-C3d agglutination of EC3d. During isolation of
the C3d-binding activity from media, EC3d-rosette inhibition
was compared to inhibition of anti-C3d agglutination of EC3d.
The anti-C3d inhibition assay not only was more sensitive but
also detected both charge and size heterogeneity in the CMd-
binding activity. C3d-Sepharose affinity chromatography and
NaDodSO4 gel analysis of the various C3d-binding activities
isolated by differences in size or charge indicated that all C3d-
binding activity was probably associated with the same 72,000
Mr protein. Thus, the probable explanation for the size and
charge heterogeneity of C3d-binding activity is that C3d-bind-
ing protein was shed from cell membranes as both individual
molecules and multivalent complexes that included various
other membrane components. The rosette inhibition assay was
apparently sensitive primarily to these large complexes of C3d-
binding protein, whereas the anti-C3d inhibition assay was sen-
sitive to the monovalent C3d-binding protein that eluted from
Sephadex G-150 with an apparent Mr of 50,000. Because Seph-
adex G-150-isolated monomers bound to C3d-Sepharose in a
similar manner as did larger C3d-binding protein complexes,
binding to the C3d matrix did not require multipoint attach-
ment. Although the C3d-binding protein was not eluted from
C3d-Sepharose by high-salt washes, complete elution required
only NP-40 in low salt (5 mS) buffer and was not enhanced by
the 0.6 M NaCl included in the NP40 elution buffer. Thus,
binding to C3d apparently involves only hydrophobic interac-
tions, and in this way differs from CR1 binding to C3-Sepharose,
which involves both salt and hydrophobic interactions (5).
Analysis of the C3d-binding protein by NaDodSO4 gel elec-
trophoresis indicated a single polypeptide chain of 50,000 ap-
parent Mr unreduced and 72,000 Mr after reduction of disulfide
bonds. This 44% increase in apparent Mr after reduction prob-
ably indicates extensive intrachain disulfide bonds. Preliminary
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FIG. 5. Analysis of NaDodSO4/7% polyacrylamide gel electrophoresis of solubilized lymphocyte antigens eluting from Sepharose-F(ab')2-anti-
C3d-binding protein. The proteins shown inA (unreduced) and B (reduced) were from BF cells (CR1+ CR2+) labeled with 1265 and lactoperoxidase.
C (unreduced) and D (reduced) show material from Raji cells (CR1- CR2+) endogenously labeled with [3H]leucine. Cqntrol eluates prepared with
radiolabeled cells and preimmune IgG contained <10% as much radioactivity as did the F(ab')2 antibody elutes and were not electrophoresed.
Molecular weight markers: myosin (MY, 200,000 Mr), 3-galactosidase (1-GZ, 116,500 Mr), phosphorylase b (PHO, 94,000 Mr), bovine serum albumin
(BSA, 68,000 Mr), ovalbumin (OVA, 43,000 Mr), and bromphenol blue tracking dye (BP).
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carbohydrate analysis indicated the presence of galactose, man-
nose, and glucosamine. The glycoprotein nature of the C3d-
binding protein was a further indication of its outer membrane
surface origin.
Antisera from rabbits immunized with the C3d-binding pro-
tein inhibited formation of B cell rosettes with EC3d but not
with EC3b or EAC14b. Analysis of antibody specificity for in-
tact cell antigens demonstrated a single protein on NaDodSO4
gels with an apparent Mr of 50,000 unreduced and 72,000 re-
duced. Because the same result was obtained with either sur-
face-iodinated or endogenously 3H-labeled cells, it is probable
that the cell-bound antigen is identical to the C3d-binding pro-
tein, and the possibility of a larger cytoplasmic precursor is ap-
parently ruled out.
Because the C3d-binding protein bound to C3d and not to
C3b or C4b, and because C3d-binding protein-specific anti-
body both inhibited B cell EC3d rosette formation and reacted
with an apparently identical B cell membrane surface protein,
it was concluded that the C3d-binding protein probably rep-
resented membrane-shed CR2. Further evidence for the CR2
origin of the C3d-binding protein was the finding of equivalent
EC3d rosette formation and immunofluorescence staining with
F(ab')2 anti-C3d-binding protein.
CR1 and CR2 are distinct and separate membrane compo-
nents. CR2 is smaller than CR1 (4, 5), and no common deter-
minants have yet been detected with either anti-CR1 or anti-
CR2 sera. Furthermore, CR1 and CR2 are probably not adjacent
on the cell surface, because saturation of B cell membranes with
Fab' anti-CR1 inhibited only CR1 rosettes (4, 5) and saturation
with F(ab')2 anti-CR2 inhibited only CR2 rosettes. Finally, even
though most normal B cells express both CR1 and CR2 simul-
taneously, a low proportion of normal B lymphocytes also ex-
press either CR1 or CR2 individually (9, 14).
Monocytes and neutrophils lacked detectable CR2 by both
rosette and immunofluorescence assay. In previous reports of
CR2 on phagocytes (8, 20, 21), complexes thought to be
EAC1-3d were in fact EAC1-3bi and contained little C3d (7,
22). C3bi attaches to neutrophil and monocyte CR3 components
that are distinct from CR1 and CR2 and unreactive with C3b,
C3d, or C4b (7, 22). Phagocyte EC3bi rosettes were unaffected
by amounts of either anti-CR1 (5) or anti-CR2 that completely
inhibited EC3b and EC3d rosettes with neutrophils and Raji
cells, respectively (Table 1).
Early studies of lymphocyte C receptors also used EAC1-3bi
thought to be EAC1-3d (1, 19). However, inhibition studies
with fluid-phase C3d (9) indicated that EAC1-3bi complexes
were at least partially bound to CR2, although it was not pre-
viously possible to assay lymphocytes specifically for CR3 by an
EC3bi rosette assay. In the present study, however, the finding
that lymphocyte EC3bi rosettes were inhibited only partially
by complete blockade of membrane CR2 with anti-CR2 (Table
1), suggested that EC3bi complexes were bound to lymphocytes
simultaneously by way of CR2 and a distinct C3bi-specific re-
ceptor (CR3) that was distinct from CR1 and CR2.
The function of lymphocyte C receptors is presently un-
known. Not only do lymphocytes express three distinct types
of C3 receptors, but also lymphocytes express surface-bound
C5 (3) and a receptor for /31H (2). Cleavage of lymphocyte sur-
face C5 leads to release of endogenous /1H and C3bINA* and
possibly also blastogenesis.t In either case, 81H and C3bINA
act upon any nearby bound C3b. When the C3b is bound to an
alternative pathway-activating surface, it is relatively resistant
to C3bINA and remains as C3b complexed to factor Bb and P
(23). By contrast, when the C3b is bound to normal tissue, then
it is rapidly converted into C3bi. C-activating surfaces will thus
bind to lymphocyte CR1 by way of C3b, and this will bring the
C3b,Bb,P enzyme into contact with surface C5. Subsequently,
the C5 would be cleaved, possibly inducing blastogenesis,t and
little CR2- and CR3-reactive C3bi would be generated. By con-
trast, when normal tissue-bound C3b is presented to a lym-
phocyte, the C3b is converted rapidly to C3bi that is bound
subsequently to CR2 and CR3 (2, *). Accordingly, it would be
predicted that whereas cleavage of surface C5 might lead to
lymphocyte blastogenesis, the engagement of CR2 and CR3
might suppress lymphocyte activation.
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